University of California San Francisco
Give to UCSF
Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC
For women with inflammatory bowel disease (IBD), pregnancy can be an uncertain time due to limited clinical data about how IBD medications impact pregnancy outcomes and infants who have been exposed
A UCSF team develops a new drug for malaria that could address one of the disease's biggest challenges - the spread of parasites that resist the most commonly-used medications.
UC San Francisco’s Paul Farmer African Initiative for Research (PFAIR) supports African scientists in infectious disease research via mentorship, international collaboration, and sustainable funding.
Endocrine disruption during pregnancy and genetic drivers of bone disease were among the topics experts from UC San Francisco presented at the annual meeting of the Endocrine Society — ENDO 2025 — in
The Byers Award recognizes outstanding research by faculty members in the middle of their careers. Martin Kampman’s honorary 2025 lecture is titled “A CRISPR approach to neurodegenerative diseases.”
A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.
UCSF researchers recently created the world's first shape-shifting synthetic proteins using artificial intelligence (AI). The breakthrough opens the door to developing entirely new proteins that could, one day, produce medicines to stop diseases like cancer.
Maria Lopez, PharmD ’01, didn’t just want to own a pharmacy – she wanted to redefine what one could be. “I wanted to create something different, something more personal,” says Lopez, the 2025 Alumni Humanitarian Service Award winner.
The School of Pharmacy’s Joanne Chun, PharmD ’93, PhD ’96, leads a new master’s degree program focused on AI’s transformation of drug discovery and development.
UCSF researchers are scouring millions of compounds – with help from tiny zebrafish – to create anesthetics safe enough to use without an anesthesiologist.
Researchers at UCSF have shown it is possible to make new proteins that move and change shape like those in nature. This ability will help scientists engineer proteins in powerful new ways to treat disease, clean up pollution, and increase crop yields.
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat
Sodium-glucose cotransporter-2 inhibitors (SGLT2i), or gliflozins, are medications used in the treatment of type 2 diabetes mellitus (T2DM). They are designed to lower high blood glucose levels
A team at UCSF and Gladstone Institutes developed new drug candidates that show great promise against the virus that causes COVID-19 and potentially other coronaviruses that could cause future pandemics.
Neuro-immunologist Stephen Hauser, MD, whose maverick thinking transformed the treatment landscape for patients with multiple sclerosis (MS), has received the 2025 Breakthrough Prize in Life Sciences.
Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.
A cancer drug developed ten years ago at UCSF can also put the brakes on one of prostate cancer's deadliest molecular tricks.
UCSF received $815 million in awards from the National Institutes of Health (NIH) last year for research that will improve the lives of patients in the U.S. and around the world.
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UC San Francisco has found.
Tuberculosis has stalked humanity for as nearly as long as we've been on earth. In this article, we take a look at how UCSF is leading the fight against the leading infectious disease killer.
UCSF scientists discover how cancer cells hijack the protein factory of the cell to churn out MYC protein, the driver of 70% of all cancers.
During COVID-19, researchers found that low-dose buprenorphine initiation for fentanyl users was largely unsuccessful, with repeated attempts also failing.
An extended course of Paxlovid appears to help some patients with long COVID, according to a study by UCSF researchers that suggests this treatment option holds promise for some of those struggling with lasting symptoms.
Nearly 50 UCSF researchers have been named to Clarivate’s list of most influential scientists for 2024.
UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer therapies with minimal side effects.
New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new